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23 A biopreservative derived from the fermentation of a dairy byproduct by 
 
24 Enterococcus faecalis UGRA10 strainis being developed. This product possesses a strong 
 
25 and wide antibacterial spectrum mainly due to the presence of Enterocin AS-48 in its 
 
26 composition. To assess its potential as food additive, the mutagenicicity and genotoxicity 
 
27 has been assayed by means of the bacterial reverse-mutation assay in Salmonella 
 
28 typhimurium TA97A, TA98, TA100, TA102, TA1535 strains (Ames test, OECD 471) 
 
29 and the micronucleus test (MN) (OECD 487) in L5178Y/ Tk+/- cells. The results in the 
 
30 Ames test after exposure to the byproduct (6.75-100 µg/plate) with absence and presence 
 
31 of the metabolic activation system from rat liver (S9 fraction), revealed not mutagenicity 
 
32 at the conditions tested. For the MN test, the exposition to five enterocin AS-48 
 
33 concentrations (0.2-1 µg/µL) was tested in the absence and presence of S9 fraction, with 
 
34 no evidence of genotoxicity. Negative results in the mutagenicity and genotoxicity assays 
 
35 point out the good safety profile of the byproduct and support its use as additive. Further 
 


















45 1. INTRODUCTION 
 
46 Several lactic acid bacteria (LAB) can produce bacteriocins, molecules that can 
 
47 be defined as antimicrobial peptides or proteins ribosomally synthesized produced by 
 
48 bacteria with potential to inhibit the growth of food-borne pathogenic and spoilage 
 
49 bacteria (Franz et al., 2007). The interest as natural biopreservatives of bacteriocins, and 
 
50 their potential applications, alone or in combination with other natural antimicrobials is 
 
51 increasing (reviewed in Des Field et al., 2018). The genus Enterococcus belongs to LAB 
 
52 and it can be found in many foods such as milk, cheese, fermented sausages or olives 
 
53 (Foulquié- Moreno et al., 2006). Moreover, a selection of Enterococcus strains with 
 
54 promising health-promoting capacities has been used as probiotics in animal and human 
 
55 health promotion to develop the intestinal microbial balance (European Commission, 
 
56 2011). Thus, some strains are currently used as therapeutic treatments marketed as 
 
57 Cylactins (Hoffmann-La Roche, Basel, Switzerland), Fargo 688s (Quest International, 
 
58 Naarden, The Netherlands), ECOFLOR (Walthers Health Care, DenHaag, The 
 
59 Netherlands), or Symbioflor 1 (SymbioPharm, Herborn, Germany). In addition, the 
 
60 production of potent bacteriocins (enterocins) is a trait frequently found in enterococcal 
 
61 strains which reinforce the probiotic potential of this group of lactic bacteria (Foulquié- 
 
62 Moreno et al., 2006). 
 
63 Enterococcus faecalis UGRA10 strain has been isolated from a raw sheep’s milk 
 
64 farmhouse cheese and can produce a fermentation product rich in Enterocin AS-48 
 
65 (Cebrian et al., 2012). AS-48 is a circular bacteriocin which shows activity mainly against 
 
66 many Gram-positive bacteria highlighting Listeria, Bacillus, Enterococcus, Planococcus, 
 
67 Mycobacterium, Corynebacterium and Nocardia. Although it also affects various Gram- 
 
68 negative species, these are much less sensitive due to the outer membrane protective 
 
69 effect (Gálvez et al., 1989). Furthermore, the activity of Enterocin AS-48 against 
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70 flagellate protozoa (Leishmania and Trypanosoma) has been recently described 
 
71 (Abengózar et al., 2017; Martinez-Garcia et al., 2018). All these antimicrobial properties 
 
72 confer to the Enterocin AS-48 several biotechnological properties with application in the 
 
73 food industry. Among them, the most extensively investigated application is its use as 
 
74 food biopreservative, because currently, natural products such bacteriocins produced by 
 
75 LAB has been demanded by consumers instead of chemical additives with potential 
 
76 health risks (Baños et al., 2019a). This bacteriocin has a great potential to control bacterial 
 
77 growth in animal food such as meats, dairy products, seafood, and also vegetable-based 
 
78 food (Ananou et al., 2010; Baños et al., 2016; Baños et al., 2019b). 
 
79 There are several studies describing the mechanism of action of AS-48,  its 
 
80 molecular structure and efficacy as an antimicrobial (Sanchez-Barrera et al., 2003). 
 
81 However, there are very few studies carried out in relation to its toxicological profile so 
 
82 far. Specifically, Cebrian et al. (2019) have described a safe profile of this substance after 
 
83 conducting different in vitro and in vivo studies. These authors demonstrated that AS-48 
 
84 exhibit low haemolytic activity in blood, it did not induce nitrite accumulation in non- 
 
85 simulated RAW macrophages and possess low cytotoxicity in several human cell lines.. 
 
86 In vivo, the assessment of AS-48 toxicity in zebrafish eggs was also performed and 
 
87 showed no visible anomalies after 24 and 48 h in embryos exposed to low doses (0.6–3.0 
 
88 mM), and the lethal dose 50 (LD50) was established between 3.0 at 6.4 µM. The authors 
 
89 also reported the absence of lymphocyte proliferation after skin sensitization in mice, and 
 
90 lack of toxicity in this experimental model (Cebrian et al., 2019). Also, the subchronic 
 
91 studies on AS-48 toxicity carried out feeding mice with enterocin for 90 days revealed 
 
92 the absence of any adverse effect on animal health (Baños et al, 2019a). However, there 
 
93 are no genotoxicity and mutagenicity studies, of key importance to evidence its safety 
 
94 prior its approval and commercialization as food additive. 
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95 Accordingly, the purpose of this research was to assess the mutagenic and 
 
96 genotoxic potential of a UGRA10 fermented product rich in Enterocin AS-48 through 
 
97 two different in vitro tests recommended by EFSA Scientific Committee: The bacterial 
 
98 reverse-mutation assay in five strains of Salmonella typhimurium (Ames test, OECD 471) 
 
99 which detects gene mutations in the absence and presence of the microsomal fraction S9; 
 
100 and the Micronucleus test (MN, OECD 487) on L5178Y Tk+/- cells that detects 
 
101 clastogenic and aneugenic chromosome aberrations in the absence and presence of the 
 
102 external metabolic activation system from rat livers, the microsomal fraction S9. 
 
103 2. MATERIALS AND METHODS 
 
104 2.1. Chemicals and Reagents 
 
105 Lactic product fermented by the UGRA10 strain containing 10 µg/µL of Enterocin 
 
106 AS-48 was provided by DMC Research Center (Granada, Spain). Chemicals for different 
 
107 assays were supplied by Gibco (Biomol, Sevilla, Spain), Sigma -Aldrich (Madrid, Spain), 
 
108 C-Viral S.L. (Sevilla, Spain) and Moltox (Trinova, Biochem, Germany). 
 
109 2.2. Bacteria Reverse Mutation Test (Ames test) 
 
110 The Ames test was performed following the OECD Guideline 471 (2020) and 
 
111 Díez-Quijada et al. (2019). Five Salmonella typhimurium histidine-auxotrophic strains 
 
112 (TA97, TA98, TA100, TA102 and TA1535) obtained from TRINOVA BIOCHEM 
 
113 GmbH (Germany) were cultured following the supplier instructions. The mutagenic 
 
114 activity of the lactic fermented product was assessed in the absence and presence of the 
 
115 external metabolic activation system from rat livers (S9 fraction). According to OECD 
 
116 471 guideline, each experiment was performed with five decreasing concentrations of 
 
117 Enterocin AS-48 (100-6.75 µg/plate) starting from its maximum concentration present in 
 
118 the lactic  fermented  product which did not present bactericidal properties. Also, a 
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119 negative control (distilled sterile water), solvent control (DMSO) and a positive control 
 
120 for each strain in accordance with the presence or absence of S9 fraction were included: 
 
121 9-Aminoacridine (50 µg/plate) was the positive control for TA97A without S9 fraction; 
 
122 2-Nitrofluorene (2-NF) (0.1 µg/plate) for TA98; sodium azide (NaN3) (1 µg/plate) for 
 
123 TA100 and TA1535; and mitomycin C (MMC) (2.5 µg/plate) for TA102. The positive 
 
124 control in the presence of S9 fraction was 2-aminofluorene (2-AF) (20 µg/plate) for all 
 
125 strains. At least 3 independent experiments were performed using triplicate plates for each 
 




128 2.3. Micronucleus test 
 
129 This assay was performed according to the OECD guideline 487 (2016). L5178Y/ 
 
130 Tk+/- cells were seeded at a concentration of 2.0×105 cell/mL and treated with five 
 
131 different concentrations of Enterocin AS-48 (0.2-1 µg/µL) selected according to the 
 
132 OECD 487 guideline and checking previously the absence of cytotoxicity. Moreover, 
 
133 these concentrations are in accordance with the highest concentration of Enterocin AS- 
 
134 48 available in the lactic fermented product (1 µg/µl) and the maximun concentration of 
 
135 use in the food industry. The experiment was performed in the absence of S9 during 24 h 
 
136 and presence of S9 during 4 h. Moreover, negative control: RPMI medium, and positive 
 
137 controls: mitomycin C (0.0625µg/mL) and colchicine (0.0125µg/mL) for clastrogens and 
 
138 aneugenic damage respectively in the absence of S9 fraction, and cyclophosphamide 
 
139 (8µg/mL) in the presence of S9 fraction were employed. After these periods, cells were 
 
140 exposed to cythochalasin B (6 µg/mL) for 20 h to block cytokinesis and obtain 
 
141 binucleated cells. Then, cultures were centrifuged, and the sedimented cells were 
 
142 subjected to a hypotonic treatment with KCl. Afterwards, the cells were again centrifuged 
 
143 and fixed. The resultant pellets were resuspended, dropped on microscope slides, and 
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144 stained with Giemsa 10%. The frequency of binucleated cells with micronuclei (BNMN) 
 
145 and the nuclear division index (NDI) were analysed according to the recommendations 
 
146 of OECD 487 (2016) by analysing at least 2000 binucleated cells per concentration. 
 
147 2.4. Statistical Analysis 
 
148 The statistical analysis was performed with Graph-Pad InStat software (Graph- 
 
149 Pad Software Inc., La Jolla, CA, USA). The non-parametric Kruskal-Wallis test was 
 
150 employed to compare the exposed samples with the negative controls. Differences were 
 
151 considered significant at * p < 0.05, ** p < 0.01 and *** p < 0.001, respectively. 
 
152 3. RESULTS AND DISCUSSION 
 
153 In general, the toxicological studies performed with bacteriocins are very scarce 
 
154 and are mainly focused on analysis of their haemolytic activity and cytotoxicity potential 
 
155 in tumour cell lines, such as the case of Enterotoxin AS-48 (Baños et al., 2019b; Cebrian 
 
156 et al., 2019). 
 
157 Regarding the Enterocin AS-48, in the present work, no signals of mutagenicity 
 
158 during the Ames test performance have been observed. The increasing concentrations of 
 
159 Enterocin AS-48 did not induce changes in the number of colonies in any of the S. 
 
160 typhimurium strains with and without S9 fraction (Table 1). MI higher than 2 was not 
 
161 obtained in any of the assayed experimental conditions. Solvent control (DMSO) did not 
 
162 induce statistically significant changes versus the negative controls. All positive controls 
 
163 show very significant differences from negative controls p <0.01. Regarding the MN test, 
 
164 the number of binucleated cells with micronucleus (BNMN) did not increase at any 
 
165 concentrations of Enterocin AS-48 assayed, and no significant differences were observed 
 
166 in comparison to the negative control with and without S9 fraction (Table 2). The NDI 
 
167 did not show any sign of toxicity without S9 fraction; however, with S9 fraction a 
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168 statistically significant increase of NDI was observed at the highest concentration (1 
 
169 µg/µL) (p < 0.05). All positive controls show significant differences from negative 
 
170 controls (p <0.001). 
 
171 The negative results obtained in these two tests evidence that Enterocin AS-48 
 
172 lacks genotoxicity and mutagenicity. No previous studies have been found in the 
 
173 scientific literature on this matter, as far as we know. Only an in vitro study reported the 
 
174 antigenotoxic effects of LAB, prebiotics and products of their fermentation by application 
 
175 of the comet assay in caco-2 cells (Nowak et al. 2015). The mechanisms involved in 
 
176 genotoxicity reduction by pro- and prebiotics are still not fully understood. 
 
177 Globally, and as it has been stated before, in vitro toxicity studies regarding 
 
178 enterocins are scarce. Specifically, there are studies that show cytotoxic effects of nisin Z 
 
179 in melanoma cells (Lewies et al., 2018), enterocin B, A + B in Hela, HT29 and AGS cells 
 
180 (Ankaiah et al., 2018) or S37 in Caco-2/TC27 cells (Belguesmia et al., 2011). Nowadays, 
 
181 the commercialized bacteriocin most widely used as food preservative is Nisin (E234), a 
 
182 bacteriocin naturally synthesized by Lactococcus lactis. Regarding Enterocin AS-48, 
 
183 Cebrian et al. (2019) had carried out in vitro studies to know its cytotoxicity through the 
 
184 MTT assay in  CCD18Co  and MCF10A cells, using 0.19 mg /  mL as  the highest 
 
185 concentration and it did not produce any decrease in cell viability. In the present work, 
 
186 up to 500 times higher concentrations (100 mg/mL in the MN assay) have been used and 
 
187 no signs of genotoxicity have been observed. 
 
188 On the other hand, the in vivo testing of AS-48 is very limited. A study performed in mice 
 
189 intraperitoneally administered (i.p.) with 5 mg/kg AS-48 (100 µg/mouse) in 6 doses (one 
 
190 every 8 h) revealed that this enterotoxin did not produce toxic effects, such as changes in 
 
191 body mass or splenomegaly (Cebrián et al., 2019). In addition, a subchronic study (90- 
 
192 days) of enterocin AS-48 in rat, indicated the absence of clinical symptoms, and no 
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193 differences in biochemical and haematological parameters in rats exposed to 200 mg/kg 
 
194 Enterocin AS-48 (Baños et al., 2019a). EFSA recommends a gradual approach to the 
 
195 generation and evaluation of information on the genotoxic potential of food additives that 
 
196 begins with a core battery of in vitro tests including a bacterial reverse mutation assay 
 
197 and in vitro assay MN test (EFSA, 2012). Additionally, one in vivo study must always be 
 
198 provided even if all of the in vitro studies are negative (EFSA, 2017). Despite to the 
 
199 absence of genotoxicity and mutagenicity of this fermentation product based on Enterocin 
 
200 AS-48, further toxicological studies such as in vivo studies are needed in order to 
 
201 demonstrate its safety, before its commercial application. 
 
 
202 5. CONCLUSION 
 
203 The lactic E. faecalis UGRA 10 fermented product rich in Enterocin AS-48 has 
 
204 no mutagenic and genotoxic effects when Ames and Micronucleus tests have been 
 
205 applied, with and without S9 fraction. However, further toxicological studies must be 
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309 Table captions: 
 
310 Table 1. Results of the Ames test obtained from the lactic UGRA10 fermentation product 
 
311 (based on Enterocin AS-48) in three independent experiments by triplicate. Milli Q water 
 
312 was used as negative control (100 µl) and DMSO (10 µl) as solvent for positive controls. 
 
313 Data are given as mean ± SD revertants/plate. Positive controls without S9 for TA97A: 
 
314 9-aminoacridine (50 µg/plate), TA98: 2-nitrofluorene (0.1 µg/plate), TA100 and 
 
315 TA1535: NaN3 (1.5 µg/plate) and TA102: mytomicin C (2.5 µg/plate). Positive control 
 
316 for all strains with S9: 2-aminofluorene (20 µg/plate). ** p<0.01 very significant 
 
317 differences from controls. 
 
318 Table 2. The frequency of micronucleus (MN) and nuclear division index (NDI) in 
 
319 cultured mouse lymphoma cells L5178-Y Tk+/- treated with the lactic UGRA10 
 
320 fermentation product (based on Enterocin AS-48). The genotoxicity assay was performed 
 
321 in absence and presence of the metabolic fraction S9. The values are expressed as mean 
 
322 ± SD. The significance levels observed are * p<0.1 and *** p<0.001 in comparison to 
 











Table 1. Results of the Ames test of the Lactic fermentation product (Enterocin AS-48) in three independent experiments by triplicate. Milli Q water was used as negative control (100 µl) and DMSO (10 µl) as solvent 
for positive controls. Data are given as mean ± SD revertants/plate. Positive controls without S9 for TA97A: 9-aminoacridine (50 µg/plate), TA98: 2-nitrofluorene (0.1 µg/plate), TA100 and TA1535: NaN3 (1.5 µg/plate) 
and TA102: mytomicin C (2.5 µg/plate). Positive control for all strains with S9: 2-aminofluorene (20 µg/plate). **p<0.01 very significant differences from controls. 
 
Concentration (µg/plate) TA97A TA98 TA100 TA102 TA1535 
  -S9 MI +S9 MI -S9 MI +S9 MI -S9 MI +S9 MI -S9 MI +S9 MI -S9 MI +S9 MI 
 Negative                     
 controls 193±18 - 179±76 - 19±6 - 22±1 - 124±12 - 87±17 - 255±73 - 190±35 - 15±2 - 14±4 - 
 
100 195±12 1.0 161±46 0.9 24±3 1.3 27±2 1.2 105±13 0.8 98±13 1.1 212±20 0.8 109±38 0.6 15±1 1.0 10±5 0.7 
 
50 195±13 1.0 238±55 1.3 18±4 0.9 23±3 1.1 86±6 0.7 94±11 1.1 280±26 1.1 116±13 0.6 11±1 0.8 12±2 0.9 
Enterocin 
AS-48 
25 212±17 1.1 129±13 0.7 23±7 1.2 22±2 1.0 82±4 0.7 89±12 1.0 219±6 0.9 104±25 0.5 13±2 0.9 13±4 0.9 
 12.5 200±18 1.1 205±45 1.1 17±2 0.9 21±3 1.0 79±9 0.6 87±16 1.0 281±14 1.1 100±9 0.5 14±3 0.9 12±5 0.8 
 



















































































































Table 2. The frequency of MN and NDI in cultured mouse lymphoma cells L5178-Y treated with the fermented product (based on Enterocin AS-48). The genotoxicity assay was performed in absence and presence of the 






Absence of S9 Presence of S9 
Treatment 
time (h) 
Concentrations BNMN (%) ± SD NDI ± SD Treatment 
time (h) 
Concentrations BNMN (%) ± SD NDI ± SD 






Mitomycin C 0.0625 
µg/mL 


















0.2 µg/µl 0.9±0.2 1.3±0.1  
 
3-6 
0.2 µg/µl 0.6±0.2 1.7±0.1 
0.4 µg/µl 0.9±0.3 1.4±0.1 0.4 µg/µl 0.7±0.1 1.6±0.0 
0.6 µg/µl 1.0±0.3 1.4±0.1 0.6 µg/µl 0.6±0.2 1.7±0.1 
0.8 µg/µl 0.9±0.1 1.4±0.1 0.8 µg/µl 1.1±0.1 1.7±0.1 
1 µg/µl 1.3±0.4 1.5±0.0 1 µg/µl 1.3±0.3 1.8±0.1* 
 
